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Abstract
Chronic hyperleptinemia may contribute to various complications of obesity includ-
ing atherosclerosis, however, the underlying mechanisms are incompletely clear. We 
examined the effect of leptin on platelet activity by measuring stable metabolites 
of thromboxane A2 (TXA2), TXB2, 11-dehydro-TXB2 and 2,3-dinor-TXB2, in plasma and 
urine. In vitro, leptin stimulated TXB2 formation by platelet-rich plasma (PRP). In vivo, 
leptin (1 mg/kg ip.) increased urinary excretion of 11-dehydro-TXB2 and 2,3-dinor-
TXB2. Urinary excretion of these metabolites was also elevated in rats made hyper-
leptinemic by administration of recombinant leptin (0.5 mg/kg/day) for 8 days. The 
stimulatory effect of leptin on TXB2 formation in PRP isolated from hyperleptinemic 
animals was impaired in comparison to the control group. In rats made obese, hy-
perleptinemic and hyperinsulinemic/insulin resistant by cafeteria diet administered 
for 3 months, acute stimulatory effect of leptin on TXB2 formation by PRP was not 
impaired. In rats made insulin resistant by fructose feeding for 8 weeks, stimulatory 
effect of leptin on TXB2 formation in PRP was augmented in comparison to the con-
trol group. Insulin sensitizer, rosiglitazone, decreased insulin level and attenuated the 
stimulatory effect of leptin on TXB2 formation in obese and fructose-fed animals. In 
contrast, rosiglitazone had no effect on insulin level or leptin-induced TXB2 formation 
in control rats and rats receiving recombinant leptin for 8 days. These results indicate 
that: (i) leptin stimulates platelet TXA2 formation both in vitro and in vivo, (ii) chronic 
hyperleptinemia impairs acute stimulatory effect of leptin on platelet activity if insulin 
sensitivity is normal, (iii) insulin resistance/hyperinsulinemia augments the stimula-
tory effect of leptin on TXA2 formation, which results in normal platelet sensitivity to 
leptin in obesity associated with both hyperleptinemia and hyperinsulinemia, and (iv) 
PPAR-γ agonists such as rosiglitazone decrease platelet sensitivity to leptin by reduc-
ing insulin resistance.
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Introduction
Re�e�t st�d�es ��d��ate t�at a� ad��
pose t�ss�e �ormo�e, lept��, �s ���
volved �� at�ero�e�es�s. Plasma lept�� 
�o��e�trat�o� �s markedly ���reased 
�� o�ese ��ma�s a�d �� a��mals ��t� 
o�es�ty ��d��ed �y ������alor�e d�et. 
�� exper�me�tal st�d�es lept�� �as 
�ee� demo�strated to �ave ma�y po�
te�t�ally proat�ero�e��� effe�ts. Th�s 
ad�pok��e ��d��es e�dot�el�al dys�
f���t�o�, ox�dat�ve stress, vas��lar 
smoot� m�s�le �ells �ypertrop�y a�d 
prol�ferat�o�, st�m�lates ma�rop�a�e 
��olesterol sy�t�es�s, a�d red��es 
�DL ��olesterol level (1). Defi��e��y 
of lept�� or �ts re�eptor red��e at�ero�
s�leros�s �� �lass�� a��mal models s��� 
as apol�poprote�� � a�d LDL re�eptor 
k�o�ko�t m��e, ��ereas adm���stra�
t�o� of exo�e�o�s lept�� �� s�prap�ys�
�olo���al doses or tra�s�e��� �ormo�e 
overexpress�o� �ave t�e oppos�te ef�
fe�t (2). �� add�t�o�, ma�y �l����al 
st�d�es ��d��ate t�e l��k �et�ee� ���� 
lept�� level a�d at�eros�leros�s, a��te 
�ard�ovas��lar eve�ts a�d �s��em�� 
stroke �� ��ma�s (3).
 Platelets play a �r���al role �� 
at�eros�leros�s. Format�o� of platelet�
r��� t�rom��s o� t�e r�pt�red plaq�e, 
��t� res�lt��� �omplete or almost 
�omplete vessel o��l�s�o�, �s t�e ma�
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�or me��a��sm of a��te �ompl��at�o�s of at�eros�leros�s s��� 
as myo�ard�al ��far�t�o� a�d �s��em�� �ere�ral stroke. �� add��
t�o�, ��ro��� lo���rade platelet a�t�vat�o� fa��l�tates �ro�t� of 
at�eros�lerot�� plaq�e. Platelets se�rete several med�ators ����� 
pote�tly st�m�late �ypertrop�y a�d prol�ferat�o� of vas��lar 
smoot� m�s�le �ells ���l�d��� platelet�der�ved �ro�t� fa�tor 
a�d t�rom�oxa�e A2 (TXA2). Moreover, a�t�vated platelets fa�
��l�tate le�ko�yte re�r��tme�t to t�e e�dot�el��m �y se�ret��� 
��emota�t�� a�d pro��flammatory med�ators s��� as a ��emok�
��e platelet fa�tor�4, a CD40 l��a�d, P�sele�t��, t�rom�ospo��
d���1 a�d RA�T�S (4).
 The effe�t of lept�� o� platelet f���t�o� �s �o�trovers�al. Some 
st�d�es �ave demo�strated t�at lept�� a��me�ts ADP���d��ed 
platelet a��re�at�o� (5), ��t ot�er a�t�ors o�served �o effe�t 
(6). These st�d�es �ere performed in vitro, a�d �t �s �ell�k�o�� 
t�at platelet a��re�at�o� in vitro �s at �est o�ly a �r�de est�mate 
of t�e�r f���t�o� �� t�e ��ta�t or�a��sm (7). Alt�o��� t�e pos��
t�ve �orrelat�o� �et�ee� ser�m lept�� a�d �r��ary ex�ret�o� of 
TXA2 meta�ol�te, 11�de�ydro�TXB2, �as �ee� o�served �� o�ese 
�ome� (8), t��s �orrelat�o� d�sappeared after ad��stme�t for a��
t�ropometr�� var�a�les s���est��� t�at �t represe�ts t�e effe�t of 
o�es�ty a�d �ot �e�essar�ly of lept�� �tself. �� add�t�o�, res�sta��e 
to ma�y effe�ts of lept�� �as �ee� des�r��ed �� o�es�ty. �t �s ���
�lear �f platelets’ se�s�t�v�ty to lept�� �s preserved or �mpa�red �� 
o�es�ty. �f platelets rema�� se�s�t�ve to lept��, ��ro��� �yperlep�
t��em�a �o�ld �o�tr���te to platelets’ �ypera�t�v�ty o�served �� 
t�e meta�ol�� sy�drome. �o�ever, �f platelets �e�ome res�sta�t 
to lept��, t�e �o�tr���t�o� of t��s ad�pok��e to at�erot�rom�ot�� 
�ompl��at�o�s �o�ld �e less l�kely.
 To address t�ese �ss�es, �� t�e prese�t st�dy �e exam��ed t�e 
effe�t of lept�� o� platelet f���t�o�, meas�red as TXA2 prod���
t�o�, �� t�e rat �ot� in vitro a�d in vivo. �� add�t�o�, �e �om�
pared t�e effe�t of lept�� �� lea� a��mals a�d �� sele�ted models 
of t�e meta�ol�� sy�drome. We also tested t�e effe�t of ros��l�ta�
zo�e, a PPAR�γ a�o��st, o� lept�����d��ed TXA2 format�o�.
Materials and methods
Animals
All st�d�es �ere performed o� ad�lt male W�star rats �e������ 
314 ± 8 �. The a��mals �ere �o�sed ��der �o�trolled �o�d�t�o�s 
of temperat�re (20�22°C), ��m�d�ty (60�70%), l���t��� (12 � 
l���t/dark �y�le) a�d prov�ded ��t� food a�d �ater ad libitum. 
The st�dy proto�ol �as rev�e�ed a�d approved �y t�e lo�al ���
st�t�t�o�al et���al �omm�ttee.
Effect of leptin on TXA2 production in vitro
Rats �ere a�est�et�zed ��t� pe�to�ar��tal (50 m�/k� �p.) a�d 
�lood �as ��t�dra�� from t�e a�dom��al aorta �s��� sod��m 
��trate as a� a�t��oa��la�t. Blood �as �e�tr�f��ed at 150×� for 
15 m�� at a room temperat�re to o�ta�� platelet�r��� plasma 
(PRP). PRP �as d�l�ted ��t� Tyrode’s ��ffer (5 mM ��P�S, 2 
mM M�Cl2, 0.1% BSA a�d 0.1% D��l��ose) to a sta�dard �o��
�e�trat�o� of 3 × 108 platelets/ml. To o�ta�� platelet�poor plasma 
(PPP), PRP �as re�e�tr�f��ed at 1000 × � for 15 m�� a�d t�e 
s�per�ata�t �as �olle�ted. PRP �as �����ated ��t� lept�� for 10 
m�� a�d TXB2 �o��e�trat�o� �as meas�red (see �elo�).
Effect of leptin on TXA2 production in vivo
Rats �ere a�est�et�zed ��t� et�yl�reta�e (1.25 �/k� �p.). The�, a 
polyet�yle�e �at�eter �as ��serted ��to t�e �r��ary �ladder for 
�r��e �olle�t�o�. Ur��e �as �olle�ted for 1 �o�r a�d t�e� e�t�er 
lept�� (1 m�/k� �� 0.5 ml) or a� eq��vol�me amo��t of p�os�
p�ate���ffered sal��e (PBS) �as ���e�ted ��traper�to�eally. Ur��e 
�olle�t�o� �as �o�t���ed for add�t�o�al 2 �o�rs. After t�e e�d of 
�r��e �olle�t�o�, a��mals �ere e�t�a��zed �y t�e let�al dose of 
pe�to�ar��tal.
Induction of hyperleptinemia, dietary-induced obesity 
 and fructose-induced metabolic syndrome
�xper�me�tal �yperlept��em�a �as ��d��ed �y adm���strat�o� 
of exo�e�o�s re�om���a�t lept�� (0.25 m�/k� t���e da�ly s�.) 
for 8 days as des�r��ed �y �s prev�o�sly (9). Lept�� �as ���e�ted 
�et�ee� 7.00 a�d 8.00 AM a�d �et�ee� 7.00 a�d 8.00 PM. The 
last dose �as ��ve� �� t�e mor���� a�d plasma for �� v�tro ex�
per�me�ts �as o�ta��ed 6 �o�rs after t��s ���e�t�o�. A��mals �� 
t��s �ro�p re�e�ved sta�dard rat ��o� ad l���t�m. ��es�ty �as 
��d��ed �y offer��� t�e a��mals a ����ly palata�le “�afeter�a 
d�et” for e�t�er 1 or 3 mo�t�s. Th�s d�et �o�s�sted of sta�dard 
��o� �om���ed 1:1 (�t/�t) ��t� a l�q��d d�et �o�ta����� eq�al 
amo��ts of s��rose, �l��ose, ��ole m�lk po�der a�d soy�ea� 
po�der s�spe�ded �� tap �ater (10). The �ompos�t�o� of t��s 
d�et �as s�m�lar to sta�dard ��o� (66% �ar�o�ydrates, 20% 
prote��, a�d 14% fat). �� t�e separate �ro�p of a��mals, fr���
tose �as adm���stered �� t�e dr��k��� �ater at a �o��e�tra�
t�o� of 20% for 8 �eeks to ��d��e �yperl�p�dem�a a�d ��s�l�� 
res�sta��e �ot asso��ated ��t� o�es�ty. �� s���ro�ps of �o�trol, 
�yperlept��em��, 3�mo�t� o�ese a�d fr��tose�fed a��mals, ���
s�l�� se�s�t�zer, ros��l�tazo�e, �as adm���stered at 10 m�/k�/
day �y oral �ava�e for 8 days �efore �lood �olle�t�o� for a��te 
�� v�tro exper�me�ts.
Measurement of TXA2 metabolites
TXA2 �s rap�dly �o�verted �o��e�zymat��ally to �ts �mmed�ate 
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meta�ol�te, TXB2, ����� �s f�rt�er e�zymat��ally meta�ol�zed to 
several der�vat�ves s��� as 2,3�d��or�TXB1, 2,3�d��or�TXB2 a�d 
11�de�ydro�TXB2 (11). Meas�reme�t of t�ese term��al meta�o�
l�tes �� �r��e prov�des a rel�a�le est�mate of ��ole��ody platelet�
der�ved TXA2. �� �o�trast, �e�a�se TXB2 �as a s�ort �alf�l�fe 
(5�7 m��), most of t��s �ompo��d fo��d �� �r��e or����ates 
from lo�al ��trare�al prod��t�o� rat�er t�a� from system�� 
so�r�es. �� t�e ot�er �a�d, �o��e�trat�o�s of 2,3�d��or�TXB2 
a�d 11�de�ydro�TXB2 �� plasma are �elo� dete�t�o� l�m�t of 
most assays ��t�l t�e sample �s �o��e�trated. �o�ever, most of 
TXB2 fo��d �� plasma �s sy�t�es�zed �y platelets ex v�vo after 
�lood ��t�dra�al. Therefore, �e �sed plasma TXB2 a�d �r��ary 
11�de�ydro�TXB2/2,3�d��or�TXB2 as markers of TXA2 forma�
t�o� for �� v�tro a�d �� v�vo st�d�es, respe�t�vely. TXB2, 11�de�
�ydro�TXB2 a�d 2,3�d��or�TXB2 �ere meas�red �y �ompet�t�ve 
e�zyme �mm��oassay (��A) met�ods �s��� Cayma� C�em��al 
k�ts (Cat. #519031, 519501 a�d 519051, respe�t�vely), a��ord��� 
to t�e ma��fa�t�rer’s ��str��t�o�. The dete�t�o� l�m�ts are 11 p�/
ml for TXB2, 16 p�/ml for 11�de�ydro�TXB2, a�d 7 p�/ml for 
2,3�d��or�TXB2.
Other assays
Plasma ��s�l�� a�d lept�� �o��e�trat�o�s �ere meas�red �y ��A 
met�ods �s��� Rat ��s�l�� ��A K�t (SP���o, Massy, Fra��e) a�d 
Lept�� ��zyme �mm��oassay K�t (Cayma� C�em��al), respe��
t�vely (10). L�p�d profile a�d plasma �l��ose �ere assayed �y 
ro�t��e la�oratory met�ods.
Reagents
Re�om���a�t rat lept�� �as o�ta��ed from R&D Systems. Ros�
��l�tazo�e �as p�r��ased from Cayma� C�em��al. �t�er rea�
�e�ts �ere from S��ma�Aldr���.
Statistical analysis
Basel��e (��t�o�t lept��) a�d lept���st�m�lated val�es of TXA2 
meta�ol�tes �� plasma a�d �r��e of t�e same a��mal �ere �om�
pared �y repeated�meas�res A��VA. Bet�ee���ro�p �om�
par�so�s of TXA2 meta�ol�tes, plasma l�p�ds, �l��ose, lept�� a�d 
��s�l�� �ere do�e �y s���le�meas�res A��VA. P<0.05 �as �o��
s�dered s����fi�a�t.
Results
Leptin stimulates TXA2 formation in vitro
Lept�� ���reased TXB2 �o��e�trat�o� �� PRP �solated from �o��
trol lea� rats �� a �o��e�trat�o��depe�de�t ma��er (F��. 1). 
Lept�� �ad �o s����fi�a�t effe�t at p�ys�olo���al �o��e�trat�o� 
(10 ��/ml) as �ell as at a moderately elevated �o��e�trat�o� (50 
��/ml), ��t s����fi�a�tly ���reased TXB2 at 100 ��/ml. Max�mal 
st�m�latory effe�t of lept�� �as o�served at 300 ��/ml (F��. 1). 
Add�t�o� of C�X ������tor, ��domet�a��� (10 μM) to t�e �lood 
�efore �solat�o� of PRP de�reased �asel��e TXB2 �o��e�trat�o� 
to 243 ± 29 p�/ml (p<0.001 vs. sample ��t�o�t ��domet�a���) 
a�d a�ol�s�ed t�e st�m�latory effe�t of lept�� (100 ��/ml lep�
t�� + ��domet�a���: 279 ± 31 p�/ml). �� add�t�o�, lept�� �ad �o 
s����fi�a�t effe�t o� TXB2 �o��e�trat�o� �� platelet�poor plasma 





















Figure 1. Effect of leptin on thromboxane B2 concentration in platelet-rich plasma (PRP) of control rats in vitro. PRP was incu-
bated in the presence of various leptin concentrations for 10 min and then TXB2 was measured. **p<0.01, ***p<0.001 vs. TXB2 
concentration in PRP not treated with leptin.
Adipobiology 1, 2009
Leptin and platelets80 RESEARCH ARTICLE
Leptin stimulates TXA2 formation in vivo
Ur��ary ex�ret�o� of 11�de�ydro�TXB2 a�d 2,3�d��or�TXB2 ���
�reased ��t��� 2 �o�rs after a s���le ��traper�to�eal lept�� ���e��
t�o� (F��. 2). �� �o�trast, lept�� �ad �o a��te effe�t o� �r��ary 
TXB2. ���e�t�o� of ve���le (PBS) ��stead of lept�� d�d �ot ��a��e 
a�y TXA2 meta�ol�te �� �r��e (�ot s�o��).
TXA2 formation is increased in rats receiving leptin for 8 days
Plasma TXB2 �o��e�trat�o� �� rats re�e�v��� exo�e�o�s lept�� 
for 8 days �as 612 ± 57 p�/ml a�d d�d �ot d�ffer from �o�trol 
�ro�p. �o�ever, �r��ary ex�ret�o� of 11�de�ydro�TXB2, 2,3�d��
�or�TXB2, a�d TXB2 �as ����er �� �yperlept��em�� t�a� �� �o��
trol a��mals (F��. 3). These res�lts ��d��ate t�at ��ro��� �yper�
lept��em�a ���reases system�� a�d ��trare�al TXA2 format�o�.
Acute effect of leptin on TXA2 formation
is impaired in hyperleptinemic rats
To exam��e �f ��ro��� �yperlept��em�a ��d��es res�sta��e of 
platelets to lept��, �e o�ta��ed PRP from rats made �yperlep�
t��em�� �y prev�o�s 8�day lept�� adm���strat�o� a�d t�e� st�d�
�ed a��te effe�t of lept�� o� TXB2 format�o� �� t�ese samples 
�� v�tro (F��. 4). As �a� �e see�, �� �yperlept��em�� rats lept�� 
s����fi�a�tly st�m�lated TXB2 format�o� at a �o��e�trat�o� �o 
less t�a� 300 ��/ml a�d d�d �t to a lesser exte�t t�a� �� �o�trol 
a��mals at �ot� 300 ��/ml a�d 500 ��/ml. Th�s, a��te st�m�la�
tory effe�t of lept�� o� platelet TXA2 format�o� �s �mpa�red �� 
�yperlept��em�� rats.
Effect of leptin on TXA2 formation in obese and fructose-fed rats
To exam��e �f ��ro��� “e�do�e�o�s” �yperlept��em�a asso��ated 
��t� o�es�ty �mpa�rs a��te effe�t of lept�� o� TXA2 format�o�, 
�e ��vest��ated t�e effe�t of lept�� o� TXB2 �o��e�trat�o� �� 
PRP of rats made o�ese �y ������alor�e d�et adm���stered for 
e�t�er 1 or 3 mo�t�s (F��. 5). Basel��e (��t�o�t exo�e�o�s lep�
t��) TXB2 �o��e�trat�o� �as sl���tly ��t s����fi�a�tly ����er �� 





























Figure 2. Urinary excretion of TXA2 metabolites in lean control rats before (-1) and during the first (1) and the second (2) hour 































Figure 3. Urinary excretion of TXA2 metabolites in control rats and in animals receiving exogenous leptin (0.25 mg/kg sc.) for 8 
days. Urine was collected for 1 hour in anesthetized animals. Urine collection was started 6 hours after the last leptin injection. 
*p<0.05, **p<0.01 vs. control group.
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�����at�o�, lept�� (300 ��/ml) ���reased TXB2 �o��e�trat�o� �� 
PRP of �o�trol a��mals �y 84.1% ��t �� 1�mo�t� o�ese �ro�p 
�y o�ly 49.6%. S�rpr�s���ly, �� �o�trast to s�ort�t�me o�es�ty, 
t�e effe�t of lept�� �� 3�mo�t� o�ese �ro�p �as �ot �mpa�red �� 
�ompar�so� to t�e �o�trol �ro�p (st�m�lat�o� �y 80.9%).
 Meta�ol�� ��ara�ter�st��s of �ot� o�ese �ro�ps �s prese�ted 
�� Ta�le 1. As �a� �e see�, plasma lept�� �s s�m�larly elevated 
�� �ot� o�ese �ro�ps ��t �� �o�trast to 1�mo�t� �ro�p, t�e 
3�mo�t� �ro�p ex����ts �yper��s�l��em�a (a marker of ��s��
l�� res�sta��e) a�d dysl�p�dem�a (�ypertr��ly�er�dem�a a�d lo� 
�DL���olesterol). ��s�l�� ������ts platelet f���t�o� a�d �ts ef�
fe�t �s �mpa�red �� ��s�l�� res�sta��e states (12). Therefore, �e 
�ypot�es�zed t�at ��s�l�� res�sta��e �� t�e 3�mo�t� o�ese �ro�p 
m���t paradox��ally ���rease t�e se�s�t�v�ty of platelets to lept�� 
�� �ompar�so� to 1�mo�t� o�ese �ro�p. To ver�fy t��s �ypot��
es�s, �e exam��ed t�e effe�t of lept�� �� fr��tose�fed rats, ����� 
are markedly �yper��s�l��em�� a�d �ypertr��ly�er�dem�� ��t 
o�ly sl���tly �yperlept��em�� (Ta�le 1). Lept�� (300 ��/ml) ���
�reased TXB2 �o��e�trat�o� �� PRP of fr��tose�fed a��mals to a 
m��� �reater de�ree (+153.0%) t�a� �� �o�trol rats. Th�s, fr���
tose���d��ed meta�ol�� sy�drome �s asso��ated ��t� e��a��ed 
platelet respo�se to lept��. Take� to�et�er, t�ese res�lts s���est 
t�at �� t�e 3�mo�t� o�ese �ro�p res�sta��e of platelets to lept�� 
d�e to ��ro��� �yperlept��em�a �s �o��ter�ala��ed �y �o��om��
ta�t �yper��s�l��em�a/��s�l�� res�sta��e ����� ���reases plate�




















































Figure 4. Concentration-dependent effect of leptin on TXB2 in PRP obtained from control rats and from rats made hyperleptin-
emic by previous 8-days leptin administration. **p<0.01, ***p<0.001 vs. TXB2 concentration in PRP not treated with leptin.
Figure 5. Effect of leptin on TXB2 formation in PRP of control, 1-month obese (O1), 3-month obese (O3) and fructose-fed rats. 
**p<0.01, ***p<0.001 vs. TXB2 concentration in the respective sample not treated with leptin, 
#p<0.05, ##p<0.01, ###p<0.001 vs. 
respective (treated or not treated with leptin) control group.
Adipobiology 1, 2009
Leptin and platelets82 RESEARCH ARTICLE
Rosiglitazone attenuates the effect of leptin on TXA2 formation 
in the 3-month obese and fructose-fed rats
To f�rt�er eval�ate t�e a�ove me�t�o�ed �ypot�es�s, �e exam�
��ed t�e effe�t of perox�some prol�ferator�a�t�vated re�eptor�γ 
(PPAR�γ) a�o��st, ros��l�tazo�e (R�Z), ����� ���reases ��s�l�� 
se�s�t�v�ty, o� platelet respo�se to lept�� �� var�o�s exper�me��
tal �ro�ps. Ros��l�tazo�e �ad �o effe�t o� plasma lept��, ��s��
l�� a�d l�p�d profile �� e�t�er �o�trol or �yperlept��em�� rats. 
�� add�t�o�, ros��l�tazo�e d�d �ot alter lept�����d��ed ���rease 
�� TXB2 �� PRP of t�ese a��mals (�ot s�o��). �� t�e 3�mo�t� 
o�ese �ro�p, ros��l�tazo�e �ad �o s����fi�a�t effe�t o� plasma 
lept�� (��t�o�t R�Z: 12.60 ± 1.27 ��/ml; ��t� R�Z: 10.21 ± 0.98 
��/ml), ��t de�reased plasma ��s�l�� (from 3.89 ± 0.46 to 2.57 
± 0.29 ��/ml, p<0.01) a�d tr��ly�er�des (from 1.20 ± 0.08 to 0.74 
± 0.05 mM, p<0.01). Basel��e (��t�o�t exo�e�o�s lept��) TXB2 
�o��e�trat�o� �as lo�er �� R�Z�treated t�a� �� �o��treated 
3�mo�t� o�ese rats (571 ± 27 vs. 693 ± 39 p�/ml, p<0.05). �� 
add�t�o�, lept�� (300 m�/ml) ���reased TXB2 �o��e�trat�o� �� 
R�Z�treated o�ese rats to 878 ± 87 p�/ml (+53.8%), ����� �s 
s����fi�a�tly less t�a� �� e�t�er �o�trol or R�Z���treated o�ese 
a��mals. �� t�e fr��tose�fed �ro�p, R�Z de�reased plasma ��s��
l�� (�54.6%) a�d tr��ly�er�des (�41.7%) a�d red��ed t�e st�m�la�
tory effe�t of 300 ��/ml lept�� o� TXB2 from +153.0% (p<0.01 
vs. �o�trol �ro�p) to +79.4% (p=�S vs. �o�trol �ro�p).
Discussion
Meta�ol�� sy�drome �s asso��ated ��t� ���reased r�sk of arter�al 
a�d ve�o�s t�rom�os�s (13�15). The pat�o�e�es�s of prot�rom�
�ot�� state �� t�e meta�ol�� sy�drome �s �omplex a�d ���om�
pletely ��derstood. ���reased �o��e�trat�o� of some �oa��lat�o� 
fa�tors s��� as fi�r��o�e�, fa�tor V�� a�d t�ss�e fa�tor, defi��e��y 
of a ma�or a�t�vator of fi�r��olys�s, t�ss�e plasm��o�e� a�t�vator, 
a�d ex�ess of fi�r��olys�s ������tor, plasm��o�e� a�t�vator ������
�tor�1 (PA��1) �ave �ee� reported �� pat�e�ts ��t� over�e���t/
o�es�ty. �� add�t�o�, platelet a��re�at�o� �s a��me�ted �� o�ese 
a��mals a�d ��ma�s (16), as ev�de��ed �y ���reased ADP����
d��ed platelet a��re�at�o� (6), ����er �r��ary 11�de�ydro�TXB2 
ex�ret�o� (8), plasma P�sele�t�� (17) a�d sol��le CD40 l��a�d 
levels (18). Platelets of o�ese s���e�ts are res�sta�t to ������tory 
effe�ts of prosta�y�l�� a�d ade�os��e (����� elevate ��tra�ell�lar 
�AMP) a�d ��tr�� ox�de (����� elevates ��tra�ell�lar ��MP), as 
�ell as to t�ese �y�l�� ���leot�des t�emselves (19, 20). Moreo�
ver, meta�ol�� sy�drome �s asso��ated ��t� red��ed se�s�t�v�ty 
of platelets to at least t�o �ro�ps of a�t�platelet dr��s, a�etyl�
sal��yl�� a��d a�d PY12 re�eptor ������tors, t��e�opyr�d��es (21). 
���reased e�dot�el�al �ell�platelet ��tera�t�o� �as �ee� o�served 
�� v�s�eral ad�pose t�ss�e �� m�r��e models of o�es�ty (22).
 Several st�d�es �ave demo�strated t�at lept�� a��me�ts 
ADP�, t�rom���� or �olla�e����d��ed platelet ad�es�o� a�d/or 
a��re�at�o� �� v�tro (5, 23, 24). �� add�t�o�, exo�e�o�s lept�� 
adm���stered to ��ld�type m��e a��me�ted vas��lar t�rom�os�s 
��d��ed �y vessel �all ����ry (25, 26). �� t�e prese�t st�dy �e 
exam��ed t�e effe�t of lept�� o� TXA2 format�o� �ot� �� v�tro 
a�d �� v�vo. TXA2 �s o�e of t�e most �ommo� platelet a�o��sts, 
a�d t�e most ��dely pres�r��ed a�t�platelet dr��, a�etylsal��yl�� 
a��d, red��es platelet a�t�v�ty �y ������t��� �ts sy�t�es�s. Apart 
from st�m�lat��� platelets, TXA2 �s ��volved �� at�ero�e�es�s �y 
��d����� vas��lar smoot� m�s�le �ell m��rat�o� a�d prol�fera�
t�o� (27) a�d express�o� of ad�es�o� mole��les �� e�dot�el�al 
�ells (28). To t�e �est of o�r k�o�led�e, o�ly o�e prev�o�s st�dy 
Table 1. Characteristics of experimental groups
Control Hyperleptinemic 1-month obesity 3-month obesity Fructose-fed
Body weight (g) 357 ± 5 342 ± 7 429 ± 7*** 497 ± 6*** 385 ± 9*
Triglycerides (mmol/l) 0.83 ± 0.06 0.74 ± 0.06 0.85 ± 0.05 1.20 ± 0.08*** 2.71 ± 0.19***
Total cholesterol (mmol/l) 2.05 ± 0.21 1.97 ± 0.17 1.83 ± 0.11 1.47 ± 0.12* 2.06 ± 0.15
HDL-cholesterol (mmol/l) 1.24 ± 0.07 1.25 ± 0.10 1.19 ± 0.08 0.76 ± 0.08*** 1.30 ± 0.12
Plasma glucose (mmol/l) 6.01 ± 0.29 6.09 ± 0.35 6.34 ± 0.43 6.30 ± 0.41 6.178 ± 0.39
Plasma insulin (ng/ml) 2.38 ± 0.24 2.15 ± 0.20 2.58 ± 0.32 3.89 ± 0.46* 4.99 ± 0.61***
Plasma leptin (ng/ml) 4.22 ± 0.41 13.6 ± 1.23*** 9.39 ± 0.81*** 12.60 ± 1.27*** 5.97 ± 0.52*
*p<0.05, **p<0.01, ***p<0.001, compared to control group.
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addressed t�e effe�t of lept�� o� TXA2 format�o�. �� t�at st�dy, 
Dellas et al (29) �ave demo�strated t�at lept�� ���reases TXB2 
�e�erat�o� �y �solated ��ma� platelets a�d a��me�ts t�e st�m��
latory effe�t of ADP. ��r res�lts are �o�s�ste�t ��t� t�ese data. 
Alt�o��� t�e m���mal effe�t�ve lept�� �o��e�trat�o� (100 ��/
ml) �s a�ove p�ys�olo���al level (ex�ept �� �ases of extreme o�es�
�ty), lept�� �as appl�ed o�ly for 10 m��. �t �s poss��le t�at more 
prolo��ed �����at�o� ��t� lept�� �o�ld �ave res�lted �� plate�
let st�m�lat�o� eve� at lo�er �o��e�trat�o�s of t��s ad�pok��e. 
���reased �r��ary TXA2 meta�ol�tes �� a��mals re�e�v��� lept�� 
for 8 days at doses ����� ra�sed �ts level to val�es o�served �� 
o�es�ty (Ta�le 1) �s �o�s�ste�t ��t� t��s �ypot�es�s. �� add�t�o�, 
lept�� �o��e�trat�o� �� t�e �lood perf�s��� ad�pose t�ss�e may 
�e lo�ally m��� ����er t�a� �� system�� ��r��lat�o�. Th�s, �t �s 
l�kely t�at st�m�latory effe�t of lept�� o� platelets �s releva�t �� 
pat�olo���al �o�d�t�o�s.
 ��es�ty �s asso��ated ��t� res�sta��e �ot o�ly to �e�tral 
a�ore�t�� ��t also to some per�p�eral effe�ts of lept�� (30), ����� 
part�ally res�lts from do��re��lat�o� of lept�� re�eptors a�d/
or postre�eptor s���al��� me��a��sms d�e to ��ro��� �yperlep�
t��em�a (31). �t �s �o�trovers�al �f platelets of o�ese ��d�v�d�als 
rema�� se�s�t�ve to lept�� or �e�ome lept���res�sta�t. Corso�ello 
et al (32) �ave demo�strated t�at st�m�latory effe�t of lept�� o� 
platelet a��re�at�o� �s �mpa�red �� over�e���t a�d o�ese ��d��
v�d�als. �� �o�trast, Cor��a et al (33) fo��d t�at lept�����d��ed 
platelet a��re�at�o� �as �mpa�red o�ly �� mor��dly o�ese ��t 
�ot �� over�e���t s���e�ts, a�d Dellas et al (34) o�served �or�
mal platelet se�s�t�v�ty to lept�� �� mor��dly o�ese pat�e�ts �� 
�ompar�so� to �ormal��e���t �o�trols. �ere�� �e demo�strate 
t�at �ot� �yperlept��em�a ��d��ed �� lea� rats �y adm���stra�
t�o� of exo�e�o�s lept�� a�d “e�do�e�o�s” �yperlept��em�a 
�� 1�mo�t� o�ese �ro�p are asso��ated ��t� res�sta��e to a��te 
TXA2�st�m�lat��� effe�t of lept�� in vitro. Desp�te t��s res�st�
a��e, �r��ary TXA2 meta�ol�tes are elevated �� �yperlept��em�� 
rats. These res�lts ��d��ate t�at lept�� may st�ll �o�tr���te to 
platelet �ypera�t�v�ty ��e� �ormo�e level �s markedly elevated, 
alt�o��� t�e de�ree of platelet st�m�lat�o� �s ��do��tedly lo�er 
t�a� �o�ld �ave �ee� �f platelets rema��ed lept���se�s�t�ve.
 S�rpr�s���ly, res�sta��e to lept�� �as �ot o�served �� t�e 
3�mo�t� o�ese �ro�p, alt�o��� e�do�e�o�s lept�� level te�ded 
to �e ����er �� t�ese a��mals t�a� �� t�e 1�mo�t� o�ese �ro�p. 
We �ypot�es�ze t�at desp�te poss��le do��re��lat�o� of lept�� 
s���al���, lept�����d��ed TXA2 prod��t�o� �s a��me�ted �y 
�o��om�ta�t ��s�l�� res�sta��e �� t�ese a��mals. Th�s �ypot��
es�s �s s�pported �y t�e follo���� o�servat�o�s: (�) o�ly 3�mo�t� 
o�ese rats �ere �yper��s�l��em�� (a�d t��s pres�ma�ly ��s��
l�� res�sta�t), (��) platelet se�s�t�v�ty to lept�� �as a��me�ted 
�� fr��tose�fed rats ����� �ere markedly ��s�l�� res�sta�t ��t 
relat�vely �ormolept��em��, (���) ros��l�tazo�e de�reased ��s��
l�� level a�d platelets’ respo�se to lept�� �� t�e 3�mo�t� o�ese 
a�d fr��tose�fed ��t �ot �� e�t�er �o�trol or �yperlept��em�� 
�ro�ps, a�d (�v) ��s�l�� ������ts platelet f���t�o� a�d �ts effe�t 
�s �mpa�red �� t�e meta�ol�� sy�drome (12,19,35). �evert�eless, 
ot�er expla�at�o�s �a��ot �e defi��tely ex�l�ded. For example, 
�yperl�p�dem�a promotes platelet a��re�at�o� (36), a�d �ot� 
3�mo�t� o�ese a�d fr��tose�fed a��mals �ere �yperl�p�dem��. 
�� add�t�o�, ros��l�tazo�e �ot o�ly red��ed ��s�l�� level ��t also 
�mproved l�p�d profile. W�atever t�e me��a��sm, t�e res�lts 
s���est t�at PPAR�γ a�o��sts s��� as ros��l�tazo�e may �e�efi�
��ally mod�late platelet f���t�o� �� o�es�ty/meta�ol�� sy�drome 
�y red����� t�e�r se�s�t�v�ty to lept��. �� add�t�o�, var�a�le de�
�ree of ��s�l�� res�sta��e may determ��e platelets’ se�s�t�v�ty to 
lept�� �� o�ese s���e�ts a�d may expla��, at least part�ally, �o��
trovers�al res�lts of prev�o�s st�d�es �� t��s field (32�34).
 ��terest���ly, �r��ary TXB2 ex�ret�o� �as ���reased �� t�e 
�yperlept��em�� �ro�p. ���reased ��trare�al TXA2 prod��t�o� 
may �o�tr���te to t�e developme�t of arter�al �yperte�s�o� a�d 
�ep�ropat�y d�e to �ts vaso�o�str��t���, a�t��atr��ret�� a�d 
profi�ro�e��� effe�ts. ���reased �r��ary TXB2 ex�ret�o� �as o��
served �� ma�y a��mal models of �yperte�s�o� s��� as spo��
ta�eo�sly �yperte�s�ve rat, Da�l salt�se�s�t�ve rat, fr��tose� or 
�� sy�t�ase ������tor���d��ed �yperte�s�o� as �ell as �� o�ese 
Z��ker rats ����� develop severe �ep�ropat�y (37�39). C�ro��� 
lept�� adm���strat�o� ��d��es arter�al �yperte�s�o� (9) a�d may 
��d��e �ep�ropat�y (40�41). �t rema��s to �e esta�l�s�ed �f ex�
�ess�ve ��trare�al TXA2 format�o� �o�tr���tes to t�ese lept���
��d��ed �ompl��at�o�s.
 There are several l�m�tat�o�s of t�e prese�t st�dy. F�rst, �e 
meas�red o�ly TXA2 format�o� a�d d�d �ot assess platelet f����
t�o� d�re�tly. TXA2 format�o� �s a� esta�l�s�ed marker of platelet 
f���t�o� a�d allo�ed �s to exam��e �t �ot� �� v�tro a�d �� v�vo �� 
t�e same exper�me�tal model. Se�o�d, �e exam��ed t�e effe�t of 
lept�� alo�e a�d d�d �ot address �ts ��tera�t�o� ��t� ot�er plate�
let a�o��sts. Th�rd, a��tely adm���stered lept�� ���reases �atr���
res�s (42,43). �t �o�ld �e s���ested t�at lept�� ���reased �r��ary 
11�de�ydro�TXB2 a�d 2,3�d��or�TXB2 se�o�dar�ly to ���reas��� 
sod��m ex�ret�o�. Th�s poss���l�ty seems, �o�ever, ��l�kely for 
t�e follo���� reaso�s: (�) �� �o�trast to 11�de�ydro�TXB2 a�d 
2,3�d��or�TXB2, a��tely adm���stered lept�� �ad �o effe�t o� 
TXB2 ex�ret�o�, (��) 8�day �yperlept��em�a �s asso��ated ��t� ���
�reased ex�ret�o� of TXA2 meta�ol�tes ��ereas �atr��res�s �s re�
d��ed �� t��s model (9), a�d (���) f�rosem�de ���reased �atr��re�
s�s ���le �av��� �o effe�t o� �r��ary TXA2 meta�ol�tes, ��ereas 
C�X ������tor, ��domet�a���, preve�ted lept�����d��ed ���rease 
�� TXA2 meta�ol�tes ��t �ad �o effe�t o� lept�����d��ed ���rease 
�� �atr��res�s (��p��l�s�ed o�servat�o�).
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 �� �o��l�s�o�, �e �ave demo�strated t�at �ot� a��tely a�d 
��ro���ally adm���stered lept�� ���reases TXA2 format�o� �� 
t�e rat. C�ro��� �yperlept��em�a �mpa�rs platelets’ respo�se to 
a��tely adm���stered lept�� �f ��s�l�� se�s�t�v�ty �s �ormal, �o��
ever, t�e st�m�latory effe�t of lept�� �s ��ta�t �f ��s�l�� res�sta��e 
�s �o��om�ta�tly o�served. PPAR�γ a�o��sts may �e �sef�l as 
ad����t�ve a�t�platelet t�erapy �� o�es�ty/meta�ol�� sy�drome 
�e�a�se t�ey red��e platelets’ se�s�t�v�ty to lept�� �y amel�orat�
��� ��s�l�� res�sta��e.
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